A retrospective study to demonstrate the amrubicin efficacy as a third or later line of chemotherapy in patients treated with non-small-cell lung cancer (NSCLC).

Trial Profile

A retrospective study to demonstrate the amrubicin efficacy as a third or later line of chemotherapy in patients treated with non-small-cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Amrubicin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top